SCHEMBL19499653

SCHEMBL19499653

C/C=C(/C)C(=O)OC1C(CO)OC(OC2OC(CO)C(OC(=O)/C(C)=C\C)C(O)C2O)C(O)C1O

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ AMY1A P0DUB6 1/20 0.39
▸ LGALS8 O00214 4/20 0.39
▸ LGALS3 P17931 3/20 0.39
▸ LGALS4 P56470 2/20 0.39
▸ IGF2R P11717 1/20 0.38
▸ AMY2A P04746 1/20 0.37
▸ LGALS9 O00182 1/20 0.36
▸ LGALS1 P09382 1/20 0.36
▸ LGALS7; LGALS7B P47929 1/20 0.36
▸ FGF1 P05230 1/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ SLC28A3 Q9HAS3 1/20 0.36
▸ PRKCA P17252 1/20 0.35
▸ STAT3 P40763 1/20 0.35
▸ CA1 P00915 1/20 0.35
▸ CA2 P00918 1/20 0.35
▸ CA9 Q16790 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29376308 1.00 AMY1A (0.39) AMY1ALGALS8LGALS3LGALS4IGF2R
SCHEMBL19507266 0.90 AMY1A (0.34) AMY1ALGALS8LGALS3LGALS4IGF2R
SCHEMBL29378663 0.88 LGALS8 (0.51) LGALS8LGALS3LGALS4LGALS9LGALS1
SCHEMBL19499655 0.88 LGALS8 (0.51) LGALS8LGALS3LGALS4LGALS9LGALS1
SCHEMBL24495028 0.87 LGALS8 (0.48) LGALS8LGALS3LGALS4IGF2RFGF1
SCHEMBL29379207 0.87 LGALS8 (0.45) AMY1ALGALS8LGALS3LGALS4IGF2R
SCHEMBL19499656 0.86 LGALS8 (0.47) LGALS8LGALS3IGF2RLGALS9LGALS1
SCHEMBL29375702 0.86 LGALS8 (0.47) LGALS8LGALS3IGF2RLGALS9LGALS1
SCHEMBL24495271 0.85 LGALS8 (0.48) LGALS8LGALS3LGALS4LGALS9LGALS1
SCHEMBL30768001 0.82 ENGASE (0.38) AMY1ALGALS8LGALS3LGALS4IGF2R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220177507-A1 NOVEL COMPOUND AND USE OF SAME NAGASE & CO., LTD. (JP) 2022-06-09 — — US disclosed
US-10202627-B2 Method for producing trehangelin THE KITASATO INSTITUTE (JP) 2019-02-12 — — US disclosed
US-20170306371-A1 METHOD FOR PRODUCING TREHANGELIN NAGASE & CO., LTD. (JP) 2017-10-26 — — US disclosed
US-20170306371-A1 METHOD FOR PRODUCING TREHANGELIN NAGASE & CO., LTD. (JP) 2017-10-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220177507-A1 NOVEL COMPOUND AND USE OF SAME TXNRD2, GPX4, GPX1 AMY1A 1059/4885LGALS8 3562/4885LGALS3 3592/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback